{
  "id": 17032892,
  "title": "Earnings call transcript: Nolato Q3 2026 sales rise as margins narrow",
  "url": "https://urgent.news/2026/10/29/earnings-call-transcript-nolato-q3-2026-sales-rise-as-margins-narrow",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-29T08:29:13.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-nolato-q3-2026-sales-rise-as-margins-narrow-93CH-4981820"
  },
  "original_language": "en",
  "account": "Nolato's Q3 2026 earnings call revealed a 7% rise in sales to SEK 2.5 billion, driven by growth in its medical business and materials unit. However, profitability suffered as margins narrowed to 10.5% from 11.7% a year earlier. Adjusted EBITA fell to SEK 262 million, a 4.4% decline. The decline was attributed to ramp-up costs, raw-material timing effects, and weaker automotive demand. Medical Solutions rose 9% organically, led by drug delivery, diagnostics, cardiology, and pharma packaging. Materials business posted a 27% organic growth and remained a key profit driver. Nolato completed two medical acquisitions and sold its Romanian unit as it reshaped its portfolio. Shares remained flat at $56.7 in premarket trading, near the middle of its 52-week range.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}